Starton Therapeutics

Transdermal Delivery Technology, 505(b)(2)

Starton Therapeutics is using proprietary dermal technology to provide cancer patients with continuous treatment. Continuous drug delivery has the potential to improve efficacy and tolerability for several drugs as it allows for lower overall drug exposure. Starton’s approach involves transforming FDA-approved medicines by leveraging their dermal delivery systems to establish new profiles that offer lower, but longer drug exposure and the potential for improved efficacy. Starton’s platform subcutaneous technology delivers between 50 to 90% lower area under the curve allowing patients to continue treatment with the avoidance of withdrawals and dose-limiting toxicity, inherently leading to longer progression-free survival. With their technology, Starton is advancing several programs to clinical studies.